Targeted failure of the week. Post No 61. Fostamatinib.

From here and here.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) fell $3.03 (40%) to $4.50 on Friday after partner AstraZeneca plc (LSE:AZN; NYSE:AZN) reported that fostamatinib plus methotrexate met one co-primary endpoint but missed the other in the Phase III OSKIRA-1 trial to treat rheumatoid arthritis. Fostamatinib missed the endpoint of structural preservation as measured by modified total Sharp score (mTSS) on radiographic scans from baseline to week 24 vs. placebo plus methotrexate, but met the co-primary endpoint of improving ACR20 response rate at week 24 vs. placebo. The ACR20 response rate for fostamatinib was 44-49% at week 24 vs. 34% for placebo. The double-blind, international trial enrolled 923 RA patients with an inadequate response to methotrexate.